{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T22:55:07Z","timestamp":1770677707210,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Khoon Poom Foundation"},{"DOI":"10.13039\/501100004704","name":"Office of National Research Council of Thailand","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Faculty of Medicine Ramathibodi Hospital"},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.dmpk.2016.01.005","type":"journal-article","created":{"date-parts":[[2016,2,13]],"date-time":"2016-02-13T15:38:20Z","timestamp":1455377900000},"page":"156-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels"],"prefix":"10.1016","volume":"31","author":[{"given":"Natchaya","family":"Vanwong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nattawat","family":"Ngamsamut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaowaluck","family":"Hongkaew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nopphadol","family":"Nuntamool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apichaya","family":"Puangpetch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montri","family":"Chamnanphon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananya","family":"Sinrachatanant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penkhae","family":"Limsila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2016.01.005_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature02626","article-title":"Moving towards individualized medicine with pharmacogenomics","volume":"429","author":"Evans","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.dmpk.2016.01.005_bib2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0165-6147(99)01363-2","article-title":"Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment","volume":"20","author":"Ingelman-Sundberg","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.dmpk.2016.01.005_bib3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants","volume":"93","author":"Hicks","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.01.005_bib4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1517\/17425255.2014.964204","article-title":"Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations","volume":"10","author":"LLerena","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmpk.2016.01.005_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2133\/dmpk.19.83","article-title":"Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1\/ABCB1","volume":"19","author":"Ozawa","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.01.005_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.dmpk.2016.01.005_bib7","first-page":"82","article-title":"Molecular genetic analysis of CYP2D6 and HLA-B*15:02 in Thai autistic spectrum disorder children: implication for pharmacogenetics testing and optimization of drug treatments","volume":"6","author":"Suwannarat","year":"2013","journal-title":"Thai J Genet"},{"key":"10.1016\/j.dmpk.2016.01.005_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0731-7085(02)00214-5","article-title":"Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects","volume":"30","author":"Gan","year":"2002","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.dmpk.2016.01.005_bib9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3109\/09540261.2013.825581","article-title":"Complexities of CYP2D6 gene analysis and interpretation","volume":"25","author":"Gaedigk","year":"2013","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.dmpk.2016.01.005_bib10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/1389200215666140202215316","article-title":"Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization","volume":"15","author":"Hicks","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.dmpk.2016.01.005_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.11-2-126","article-title":"Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications","volume":"11","author":"Bernard","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.dmpk.2016.01.005_bib12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.dmpk.2016.01.005_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1744-6171.2007.00112.x","article-title":"Risperidone approved for the treatment of serious behavioral problems in children with autism","volume":"20","author":"Scahill","year":"2007","journal-title":"J\u00a0Child Adolesc Psychiatr Nurs"},{"key":"10.1016\/j.dmpk.2016.01.005_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.braindev.2012.03.015","article-title":"Pharmacotherapy of autism spectrum disorders","volume":"35","author":"Benvenuto","year":"2013","journal-title":"Brain Dev"},{"key":"10.1016\/j.dmpk.2016.01.005_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","article-title":"Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects","volume":"54","author":"Huang","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.01.005_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02245444","article-title":"The regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat","volume":"114","author":"Van Beijsterveldt","year":"1994","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.dmpk.2016.01.005_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1176\/appi.psy.49.4.347","article-title":"A\u00a0preliminary attempt to personalize risperidone dosing using drug\u2013drug interactions and genetics, part II","volume":"49","author":"de Leon","year":"2008","journal-title":"Psychosomatics"},{"key":"10.1016\/j.dmpk.2016.01.005_bib18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1461145704004390","article-title":"The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein","volume":"7","author":"Wang","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.dmpk.2016.01.005_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","article-title":"Comparative pharmacology of risperidone and paliperidone","volume":"15","author":"Corena-McLeod","year":"2015","journal-title":"Drugs R D"},{"key":"10.1016\/j.dmpk.2016.01.005_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 Pki values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmpk.2016.01.005_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.euroneuro.2012.04.016","article-title":"Functional analysis of gene expression in risperidone treated cells provide new insights in molecular mechanism and new candidate genes for pharmacogenetic studies","volume":"23","author":"Mas","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.dmpk.2016.01.005_bib22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.01.005_bib23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2016.01.005_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbrc.2010.02.162","article-title":"Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system","volume":"396","author":"Ingelman-Sundberg","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.dmpk.2016.01.005_bib25","article-title":"Impact of CYP2D6 polymorphism on steady-state plasma levels of risperidone and 9-hydroxyrisperidone in thai children with autistic spectrum disorder","author":"Vanwong","year":"2016","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.dmpk.2016.01.005_bib26","unstructured":"Janssen Pharmaceuticals IRpi. http:\/\/www.janssenpharmaceuticalsinc.com\/assets\/risperdal.pdf [retrieval date: April 12, 2013]."},{"key":"10.1016\/j.dmpk.2016.01.005_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","article-title":"The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype","volume":"83","author":"Gaedigk","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.01.005_bib28","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1365\/s10337-010-1580-3","article-title":"Accuracy profile theory for the validation of an LC\u2013MS-MS method for the determination of risperidone and 9-OH risperidone in human plasma","volume":"71","author":"Zhang","year":"2010","journal-title":"Chromatographia"},{"key":"10.1016\/j.dmpk.2016.01.005_bib29","first-page":"2","article-title":"LC-MS\/MS bioanalysis method development, validation, and sample analysis: points to consider when conducting nonclinical and clinical studies in accordance with current regulatory guidances","volume":"4","author":"Whitmire","year":"2011","journal-title":"J\u00a0Anal Bioanal Tech"},{"key":"10.1016\/j.dmpk.2016.01.005_bib30","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.clinbiochem.2011.06.985","article-title":"Combination of multiplex PCR and DHPLC-based strategy for CYP2D6 genotyping scheme in Thais","volume":"44","author":"Suwannasri","year":"2011","journal-title":"Clin Biochem"},{"key":"10.1016\/j.dmpk.2016.01.005_bib31","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.cca.2010.08.042","article-title":"Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations","volume":"411","author":"Kim","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.dmpk.2016.01.005_bib32","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/JCP.0b013e3181ee84c7","article-title":"Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers","volume":"30","author":"J1","year":"2010","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.dmpk.2016.01.005_bib33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.clpt.6100455","article-title":"CYP2D6 phenotype prediction from genotype: which system is the best?","volume":"83","author":"Kirchheiner","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.01.005_bib34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/0091270009359182","article-title":"Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients","volume":"50","author":"Borges","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.01.005_bib35","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.clpt.2004.08.020","article-title":"Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension","volume":"76","author":"Zineh","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2016.01.005_bib36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/JCP.0b013e3181a289e0","article-title":"Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients","volume":"29","author":"Kang","year":"2009","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.dmpk.2016.01.005_bib37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/0091270009347867","article-title":"Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety","volume":"50","author":"Xiang","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2016.01.005_bib38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1476-5381.2011.01385.x","article-title":"Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10\/*10","volume":"164","author":"Yoo","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.dmpk.2016.01.005_bib39","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/dmcn.12470","article-title":"CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study","volume":"56","author":"Youngster","year":"2014","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.dmpk.2016.01.005_bib40","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00228-010-0876-4","article-title":"Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in\u00a0vivo dextromethorphan metabolism in a Japanese population","volume":"66","author":"Kiyotani","year":"2010","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436716000136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436716000136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:52:39Z","timestamp":1761162759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436716000136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1347436716000136"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2016.01.005","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2016.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}